For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut.

TitleCD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut.
Publication TypeJournal Article
Year of Publication2011
AuthorsSonnenberg GF, Monticelli LA, M Elloso M, Fouser LA, Artis D
JournalImmunity
Volume34
Issue1
Pagination122-34
Date Published2011 Jan 28
ISSN1097-4180
KeywordsAdoptive Transfer, Animals, CD4-Positive T-Lymphocytes, Cells, Cultured, Citrobacter rodentium, Enterobacteriaceae Infections, Enzyme-Linked Immunosorbent Assay, Immunity, Innate, Immunization, Interleukin-23, Interleukins, Intestines, Lymphocyte Depletion, Lymphoid Tissue, Mice, Mice, Inbred C57BL, Mice, Knockout
Abstract

Fetal CD4(+) lymphoid tissue inducer (LTi) cells play a critical role in the development of lymphoid tissues. Recent studies identified that LTi cells persist in adults and are related to a heterogeneous population of innate lymphoid cells that have been implicated in inflammatory responses. However, whether LTi cells contribute to protective immunity remains poorly defined. We demonstrate that after infection with Citrobacter rodentium, CD4(+) LTi cells were a dominant source of interleukin-22 (IL-22) early during infection. Infection-induced CD4(+) LTi cell responses were IL-23 dependent, and ablation of IL-23 impaired innate immunity. Further, depletion of CD4(+) LTi cells abrogated infection-induced expression of IL-22 and antimicrobial peptides, resulting in exacerbated host mortality. LTi cells were also found to be essential for host protective immunity in lymphocyte-replete hosts. Collectively these data demonstrate that adult CD4(+) LTi cells are a critical source of IL-22 and identify a previously unrecognized function for CD4(+) LTi cells in promoting innate immunity in the intestine.

DOI10.1016/j.immuni.2010.12.009
Alternate JournalImmunity
PubMed ID21194981
PubMed Central IDPMC3035987
Grant ListAI083480 / AI / NIAID NIH HHS / United States
AI087990 / AI / NIAID NIH HHS / United States
AI61570 / AI / NIAID NIH HHS / United States
AI74878 / AI / NIAID NIH HHS / United States
DK50306 / DK / NIDDK NIH HHS / United States
R01 AI061570 / AI / NIAID NIH HHS / United States
R01 AI061570-08 / AI / NIAID NIH HHS / United States
R01 AI074878 / AI / NIAID NIH HHS / United States
R01 AI074878-03S1 / AI / NIAID NIH HHS / United States
R01 AI074878-04 / AI / NIAID NIH HHS / United States
R01 AI095466 / AI / NIAID NIH HHS / United States
R21 AI083480 / AI / NIAID NIH HHS / United States
R21 AI083480-02 / AI / NIAID NIH HHS / United States
R21 AI087990 / AI / NIAID NIH HHS / United States
R21 AI087990-02 / AI / NIAID NIH HHS / United States
T32 AI007532 / AI / NIAID NIH HHS / United States
T32AI007532-08 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587